MCID: HRT012
MIFTS: 58

Heart Valve Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Heart Valve Disease

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease 39 12 15 64 17 74
Valvular Heart Disease 12 15
Heart Valve Diseases 44 45
Abnormality of the Heart Valves 6
Valvular Heart Diseases 56
Heart Valve Prolapse 45

Classifications:



External Ids:

Disease Ontology 12 DOID:4079
NCIt 51 C45525
SNOMED-CT 69 368009

Summaries for Heart Valve Disease

MedlinePlus : 44 Your heart has four valves. Normally, these valves open to let blood flow through or out of your heart, and then shut to keep it from flowing backward. But sometimes they don't work properly. If they don't, you could have Regurgitation - when blood leaks back through the valve in the wrong direction Mitral valve prolapse - when one of the valves, the mitral valve, has "floppy" flaps and doesn't close tightly. It's one of the most common heart valve conditions. Sometimes it causes regurgitation. Stenosis - when the valve doesn't open enough and blocks blood flow Valve problems can be present at birth or caused by infections, heart attacks, or heart disease or damage. The main sign of heart valve disease is an unusual heartbeat sound called a heart murmur. Your doctor can hear a heart murmur with a stethoscope. But many people have heart murmurs without having a problem. Heart tests can show if you have a heart valve disease. Some valve problems are minor and do not need treatment. Others might require medicine, medical procedures, or surgery to repair or replace the valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Valve Disease, also known as valvular heart disease, is related to rheumatic heart disease and orthostatic intolerance, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Heart Valve Disease is SMC1A (Structural Maintenance Of Chromosomes 1A), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Spinal Cord Injury. The drugs Amiodarone and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include Heart and Heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

PubMed Health : 64 About heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves.These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Wikipedia : 77 Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Related Diseases for Heart Valve Disease

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 rheumatic heart disease 32.4 ACE MYOM2 TGFB1
2 orthostatic intolerance 32.3 ELN FBN1 PDLIM1
3 tricuspid valve disease 31.8 ARSE FBN1 NPPB
4 dilated cardiomyopathy 31.4 ACE CTF1 IL1B NPPA NPPB TGFB1
5 arteries, anomalies of 31.2 ACE IL1B NPPB
6 coronary artery anomaly 31.0 ACE NPPA NPPB
7 congestive heart failure 30.7 ACE NPPA NPPB NR3C2
8 sleep apnea 30.3 ACE HTR2A IL1B NPPB
9 mitral valve disease 30.3 ACE FBN1 NPPA
10 pulmonary edema 30.3 ACE IL1B NPPA NPPB
11 tricuspid valve insufficiency 30.2 ARSE FBN1 NPPB
12 pulmonary hypertension, primary, 1 30.2 FBN1 NPPA NPPB
13 pulmonary hypertension 30.1 ACE HTR2B NPPA NPPB
14 systemic scleroderma 30.1 ACE FBN1 TGFB1
15 mitral valve insufficiency 30.1 ACE FBN1 NPPA NPPB PDLIM1
16 lung disease 30.1 ELN IL1B NPPB TGFB1
17 central sleep apnea 30.0 NPPA NPPB
18 chronic kidney failure 30.0 ACE NPPA NPPB TGFB1
19 aortic valve insufficiency 30.0 ACE ELN FBN1 NPPB
20 myocardial infarction 30.0 ACE CTF1 IL1B NPPA NPPB NR3C2
21 hypertension, essential 29.9 ACE NPPA NPPB NR3C2
22 kidney disease 29.8 ACE NPPA NPPB NR3C2 TGFB1
23 heart disease 29.7 ACE ELN IL1B NPPA NPPB
24 aortic valve disease 2 29.2 ACE CNMD ELN NPPA NPPB PDLIM1
25 short stature valvular heart disease 12.3
26 cardiac valvular defect, developmental 11.7
27 cardiac valvular dysplasia, x-linked 11.6
28 tricuspid valve stenosis 11.4
29 disproportionate short stature with ptosis and valvular heart lesions 11.3
30 andersen cardiodysrhythmic periodic paralysis 11.1
31 cardiomyopathy, familial hypertrophic, 21 11.1
32 coumarin resistance 11.0
33 sick sinus syndrome 11.0
34 atrial fibrillation 10.7
35 aplasia cutis congenita, nonsyndromic 10.6
36 esterase c 10.6
37 rere-related disorders 10.5
38 familial vesicoureteral reflux 10.4 ACE TGFB1
39 vulvar vestibulitis syndrome 10.4 IL1B IL1R1
40 chronic fatigue syndrome 10.4 HTR2A IL1B TGFB1
41 pseudoxanthoma elasticum-like papillary dermal elastolysis 10.4 ELN FBN1
42 late-onset focal dermal elastosis 10.4 ELN FBN1
43 autoimmune atherosclerosis 10.4 ACE APOH
44 familial cold autoinflammatory syndrome 1 10.3 IL1B IL1R1
45 hepatoportal sclerosis 10.3 ACE ELN
46 familial abdominal aortic aneurysm 10.3 ELN FBN1
47 hypoaldosteronism 10.3 ACE NPPA
48 silicosis 10.3 ACE IL1B TGFB1
49 anterolateral myocardial infarction 10.3 ACE NPPA NPPB
50 intermittent claudication 10.3 ACE APOH HTR2A

Graphical network of the top 20 diseases related to Heart Valve Disease:



Diseases related to Heart Valve Disease

Symptoms & Phenotypes for Heart Valve Disease

UMLS symptoms related to Heart Valve Disease:


angina pectoris, edema, chest pain, undiagnosed heart murmur

GenomeRNAi Phenotypes related to Heart Valve Disease according to GeneCards Suite gene sharing:

27 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.91 IL1B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.91 IL1B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.91 TGFB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.91 IL1R1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.91 IL1B IL1R1 TGFB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.91 TGFB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.91 IL1R1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.91 NR3C2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.91 IL1R1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.91 TGFB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.91 TGFB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 IL1B IL1R1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.91 TGFB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.91 IL1B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.91 NR3C2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.91 TGFB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.91 IL1R1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.91 NR3C2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.91 IL1B IL1R1 NR3C2 TGFB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.91 IL1B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.91 NR3C2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.91 NR3C2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.91 IL1R1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.91 TGFB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 IL1B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.91 IL1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.91 TGFB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.91 NR3C2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.91 IL1B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.91 IL1B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.91 IL1R1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.91 NR3C2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.91 IL1R1

MGI Mouse Phenotypes related to Heart Valve Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 ACE CNMD FBN1 IL1B IL1R1 NPPA
2 adipose tissue MP:0005375 9.63 ACE CTF1 FBN1 HTR2B IL1R1 TGFB1
3 muscle MP:0005369 9.17 FBN1 HTR2A HTR2B IL1R1 NPPA NR3C2

Drugs & Therapeutics for Heart Valve Disease

PubMedHealth treatment related to Heart Valve Disease: 64

Currently, no medicines can cure heart valve disease. However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve.The goals of treating heart valve disease might include:Preventing, treating, or relieving the symptoms of other related heart conditions.Protecting heart valves from further damage.Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 432)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
2
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 54678486 6691
3
Atorvastatin Approved Phase 4,Phase 3 134523-00-5 60823
4
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
5
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
6
Ranolazine Approved, Investigational Phase 4,Phase 2 95635-55-5, 142387-99-3 56959
7
Captopril Approved Phase 4 62571-86-2 44093
8
Trandolapril Approved Phase 4 87679-37-6 5484727
9
Spironolactone Approved Phase 4,Not Applicable 1952-01-7, 52-01-7 5833
10
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
11
Ketamine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 6740-88-1 3821
12
Remifentanil Approved Phase 4,Phase 2,Not Applicable 132875-61-7 60815
13
Midazolam Approved, Illicit Phase 4,Phase 2,Not Applicable 59467-70-8 4192
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
15
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
16
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2 145040-37-5 2540
17
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
18
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
19
Clopidogrel Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
20
Ticagrelor Approved Phase 4,Phase 3,Early Phase 1 274693-27-5 9871419
21
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
22 Menaquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1182-68-9
23
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84-80-0
24
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
25
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 37350-58-6, 51384-51-1 4171
26
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 113775-47-6 5311068 68602
27
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 68-04-2
28
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 28523-86-6 5206
29
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
30
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
31
Etomidate Approved Phase 4,Phase 2 33125-97-2 667484 36339
32
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
33
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
34
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
35
Dobutamine Approved Phase 4,Not Applicable 34368-04-2 36811
36
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
37
Norepinephrine Approved Phase 4 51-41-2 439260
38
Valsartan Approved, Investigational Phase 4,Phase 2,Phase 3 137862-53-4 60846
39
Tolvaptan Approved Phase 4 150683-30-0 216237
40
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
41
Aminocaproic Acid Approved, Investigational Phase 4 60-32-2 564
42 Nutmeg Approved Phase 4,Not Applicable
43
Cosyntropin Approved Phase 4 16960-16-0 16129617
44
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
45
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
46
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 9005-49-6 46507594 772
47
Losartan Approved Phase 4,Phase 2,Not Applicable 114798-26-4 3961
48
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
49
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2 58-61-7 60961
50
Regadenoson Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 313348-27-5 219024

Interventional clinical trials:

(show top 50) (show all 1405)
# Name Status NCT ID Phase Drugs
1 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
2 Frailty and Cognitive Function Assessment of TAVI Patients Unknown status NCT02650388 Phase 4
3 The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study Unknown status NCT01623193 Phase 4
4 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
5 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
6 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
7 Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Unknown status NCT01431222 Phase 4
8 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
9 The Pacing vs No Pacing Study - PNP Study Unknown status NCT02498639 Phase 4
10 Desflurane-induced Myocardial Protection Unknown status NCT02019797 Phase 4 Desflurane
11 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
12 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
13 Physiological Response to Heliox21 and Air O2 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
14 Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis Unknown status NCT00252317 Phase 4 Captopril and Trandolapril;Captopril Test Dose and Trandolapril
15 Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery Unknown status NCT01046604 Phase 4 Lovaza group
16 Endothelial Progenitors in Aortic Stenosis: Association With Aortic Stenosis Progression and Severity Unknown status NCT02060071 Phase 4
17 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
18 Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
19 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Unknown status NCT00879060 Phase 4 spironolactone
20 Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
21 Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01384643 Phase 4 Propofol
22 The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery Completed NCT01210976 Phase 4 levosimendan;placebo
23 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
24 A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation. Completed NCT00166400 Phase 4 metoprolol succinate
25 Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography Completed NCT02867930 Phase 4 Dexmedetomidine;Ketofol(ketamine+propofol)
26 Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
27 Effect of Anesthetics on CD39 and CD73 After Open-heart Surgery Completed NCT02136979 Phase 4 Propofol;Sevoflurane
28 Propofol Effects on Mitral Valve Annular Velocity Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
29 Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery Completed NCT01174719 Phase 4 volume replacement;Humanalbumin 5%;volume replacement
30 The Cortisol Levels During Cardiac Surgery. The Comparison Between Etomidate and Thiopentone Completed NCT01495949 Phase 4 etomidate;thiopentone
31 Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery Completed NCT01477151 Phase 4 Volatile anesthetic
32 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
33 The Use of Paravertebral Block for Cardiac Surgery Completed NCT02180893 Phase 4
34 The Effects of Levosimendan During Mitral Valve Surgery Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
35 Beating Versus Arrested Heart for Mitral Valve Replacement Completed NCT01641614 Phase 4
36 CG Future® Annuloplasty Ring/Band Clinical Trial Completed NCT01074671 Phase 4
37 Angiotensin-II Blockade in Mitral Regurgitation Completed NCT00587470 Phase 4 Candesartan;atacand;Placebo
38 Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation Completed NCT02687932 Phase 4 LCZ696;Valsartan
39 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
40 Tricuspid Regurgitation Study Completed NCT01093001 Phase 4
41 Cerebral Embolic Load in Patients Undergoing Surgical Aortic Valve Replacement: A Comparison of the Conventional With the Minimized Extracorporeal Circulation Technique Using Transcranial Doppler Ultrasound Completed NCT02308566 Phase 4
42 Platelet Reactivity After TAVI: A Multicenter Pilot Study Completed NCT02224066 Phase 4 Ticagrelor 90 mg twice per day during three months following TAVI;Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
43 Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation Completed NCT01157572 Phase 4 Metoprolol;Placebo
44 REST Study: Left Ventricular Regression European Study Completed NCT00256165 Phase 4
45 Effect of Neuromuscular Blockade and Reversal on Breathing Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
46 Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation Completed NCT02454582 Phase 4
47 Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis Completed NCT01060020 Phase 4 Sildenafil
48 Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis Completed NCT00156520 Phase 4 aprotonin; epsilon aminocaproic acid
49 Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients Completed NCT00665119 Phase 4 remifentanil;placebo
50 B-type Natriuretic Peptide (BNP)-Guided Diagnostic Strategy in Intensive Care Unit (ICU) Patients With Respiratory Failure Completed NCT00130559 Phase 4

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Genetic Tests for Heart Valve Disease

Anatomical Context for Heart Valve Disease

MalaCards organs/tissues related to Heart Valve Disease:

42
Heart, Lung, Testes, Kidney, Brain, Endothelial, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Atrioventricular Valves Atrioventricular Valve Cells Affected by disease
2 Heart Semilunar Valves Semilunar Valve Cells Affected by disease

Publications for Heart Valve Disease

Articles related to Heart Valve Disease:

(show top 50) (show all 1388)
# Title Authors Year
1
Quantitative proteomics of changes in succinylated proteins expression profiling in left appendages tissue from valvular heart disease patients with atrial fibrillation. ( 31059701 )
2019
2
Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis. ( 31055767 )
2019
3
LIM kinase 1 acts as a profibrotic mediator in permanent atrial fibrillation patients with valvular heart disease. ( 30837367 )
2019
4
Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study. ( 29986001 )
2019
5
The "Heart Valve Clinic" Pathway for the Management of Frail Patients With Valvular Heart Disease: From "One for All" to "All for One". ( 31094730 )
2019
6
2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: A proposal to optimize care for patients with valvular heart disease: A joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. ( 31010585 )
2019
7
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. ( 31010608 )
2019
8
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and The Society of Thoracic Surgeons. ( 31010643 )
2019
9
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. ( 31010719 )
2019
10
2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: A proposal to optimize care for patients with valvular heart disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. ( 31002751 )
2019
11
The new ESC Council on Valvular Heart Disease. ( 30768209 )
2019
12
Cost of Treatment of Valvular Heart Disease at a Tertiary Hospital in North India: Policy Implications. ( 30783991 )
2019
13
Clinical, sonographic characteristics and long-term prognosis of valvular heart disease in elderly patients. ( 30800149 )
2019
14
Ayurvedic approach to treat Hridroga (valvular heart disease): A case report. ( 30824173 )
2019
15
The year in cardiology 2018: valvular heart disease. ( 30602001 )
2019
16
Valvular heart disease in Antiphospholipid antibody syndrome: Isolated Tricuspid stenosis. ( 30614053 )
2019
17
A Young Boy with Familial Hypercholesterolemia and Valvular Heart Disease. ( 30617609 )
2019
18
Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. ( 30655975 )
2019
19
Contemporaneous management of valvular heart disease and aortopathy in aircrew. ( 30425087 )
2019
20
Valvular Heart Disease and Heart Failure in Women. ( 30449382 )
2019
21
Benefit of Four-Dimensional Computed Tomography Derived Ejection Fraction of the Left Atrial Appendage to Predict Thromboembolic Risk in the Patients with Valvular Heart Disease. ( 30468031 )
2019
22
The Complexity of Pulmonary Hypertension and Its Prognostic Importance in Patients With Valvular Heart Disease. ( 30385195 )
2019
23
Exercise recommendations in patients with valvular heart disease. ( 30262455 )
2019
24
Echocardiographic Surveillance of Valvular Heart Disease in Different Sociodemographic Groups. ( 30121267 )
2019
25
Heart Valve Disease Awareness Survey 2017: what did we achieve since 2015? ( 29943272 )
2019
26
Murmur clinic: validation of a new model for detecting heart valve disease. ( 30049836 )
2019
27
Correction to: Heart Valve Disease Awareness Survey 2017: what did we achieve since 2015? ( 30155733 )
2019
28
3D printing for heart valve disease: a systematic review. ( 30771098 )
2019
29
Heart valve disease in elderly. ( 30820277 )
2019
30
von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week. ( 30846101 )
2019
31
Bacterial infiltration in structural heart valve disease. ( 30885626 )
2019
32
Commentary: Bacterial infiltration in structural heart valve disease-Do these new insights have profound consequences? ( 30961985 )
2019
33
Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. ( 30223375 )
2018
34
Response to: 'Current recommendations for anticoagulant therapy in patients with valvular heart disease and atrial fibrillation: the ACC/AHA and ESC/EACTS Guidelines in Harmony…but not Lockstep!' ( 30482810 )
2018
35
Protein Compositions Changes Of Circulating Microparticles In Patients With Valvular Heart Disease Subjected To Cardiac Surgery Contribute To Systemic Inflammatory Response and Disorder of Coagulation. ( 30601407 )
2018
36
Profiles of hospitalized patients with valvular heart disease: Experience of a tertiary center. ( 30554887 )
2018
37
Epidemiology of valvular heart disease in Portugal: The time has come for the heart valve unit. ( 30559035 )
2018
38
Brachial-Ankle Pulse Waves Reflect the Hemodynamics of Valvular Heart Disease. ( 30560602 )
2018
39
Early Surgery in Valvular Heart Disease. ( 30334383 )
2018
40
Lifetime Risks of Valvular Heart Disease and Pacemaker Use in Patients With Ankylosing Spondylitis. ( 30371264 )
2018
41
Role of Cardiac Magnetic Resonance Imaging in Valvular Heart Disease: Diagnosis, Assessment, and Management. ( 30259253 )
2018
42
Stress echocardiography in valvular heart disease. ( 30286667 )
2018
43
Frailty and Exercise Training: How to Provide Best Care after Cardiac Surgery or Intervention for Elder Patients with Valvular Heart Disease. ( 30302342 )
2018
44
Valvular heart disease: tricuspid regurgitation is the new frontier. ( 30321339 )
2018
45
Imaging of Valvular Heart Disease in Heart Failure. ( 30206481 )
2018
46
Advanced cardiac MRI techniques for evaluation of left-sided valvular heart disease. ( 30134000 )
2018
47
The 2017 European Society of Cardiology (ESC)/European Association of Cardiothoracic Surgeons (EACTS) Guidelines for Management of Valvular Heart Disease-Highlights and Perioperative Implications. ( 29934206 )
2018
48
Junior medical student performed focused cardiac ultrasound after brief training to detect significant valvular heart disease. ( 29946563 )
2018
49
A Rare Presentation of Anterior Mediastinal Teratoma Mimicking Valvular Heart Disease with A Systolic Murmur. ( 30002584 )
2018
50
Valvular Heart Disease in a Young Israeli Ethiopian Immigrant Population From the Gondar Region With Implications for Rheumatic Heart Disease. ( 29868538 )
2018

Variations for Heart Valve Disease

ClinVar genetic disease variations for Heart Valve Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SMC1A NM_006306.3(SMC1A): c.802_804delAAG (p.Lys268del) deletion Pathogenic rs727503773 GRCh37 Chromosome X, 53439900: 53439902
2 SMC1A NM_006306.3(SMC1A): c.802_804delAAG (p.Lys268del) deletion Pathogenic rs727503773 GRCh38 Chromosome X, 53412950: 53412952

Expression for Heart Valve Disease

Search GEO for disease gene expression data for Heart Valve Disease.

Pathways for Heart Valve Disease

GO Terms for Heart Valve Disease

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 ACE APOH CTF1 FBN1 IL1B MIR205
2 extracellular region GO:0005576 9.36 ACE APOH CNMD CTF1 ELN FBN1
3 collagen-containing extracellular matrix GO:0062023 9.35 APOH ELN FBN1 NPPA TGFB1

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 CTF1 HTR2A HTR2B IL1B TGFB1
2 cytokine-mediated signaling pathway GO:0019221 9.88 CTF1 IL1B IL1R1 TGFB1
3 negative regulation of angiogenesis GO:0016525 9.79 APOH CNMD NPPB
4 response to drug GO:0042493 9.77 HTR2A HTR2B TGFB1
5 cellular calcium ion homeostasis GO:0006874 9.75 HTR2A HTR2B TGFB1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.72 HTR2A HTR2B TGFB1
7 cellular response to mechanical stimulus GO:0071260 9.69 IL1B NPPA TGFB1
8 positive regulation of histone acetylation GO:0035066 9.61 IL1B TGFB1
9 regulation of blood pressure GO:0008217 9.61 ACE NPPA NPPB
10 regulation of blood vessel size GO:0050880 9.59 NPPA NPPB
11 positive regulation of MAP kinase activity GO:0043406 9.58 HTR2A HTR2B TGFB1
12 regulation of blood vessel diameter GO:0097746 9.56 ACE NPPB
13 cGMP biosynthetic process GO:0006182 9.54 NPPA NPPB
14 response to hypoxia GO:0001666 9.54 NPPA PDLIM1 TGFB1
15 receptor guanylyl cyclase signaling pathway GO:0007168 9.52 NPPA NPPB
16 behavior GO:0007610 9.49 HTR2A HTR2B
17 cellular response to insulin-like growth factor stimulus GO:1990314 9.48 FBN1 TGFB1
18 serotonin receptor signaling pathway GO:0007210 9.46 HTR2A HTR2B
19 positive regulation of cell division GO:0051781 9.43 HTR2B IL1B TGFB1
20 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.32 IL1B IL1R1
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.16 HTR2A HTR2B
22 regulation of signaling receptor activity GO:0010469 9.1 CTF1 FBN1 IL1B NPPA NPPB TGFB1
23 mononuclear cell proliferation GO:0032943 8.96 ACE TGFB1

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 FBN1 NPPA NPPB
2 drug binding GO:0008144 9.33 ACE HTR2A HTR2B
3 serotonin binding GO:0051378 9.26 HTR2A HTR2B
4 extracellular matrix constituent conferring elasticity GO:0030023 8.96 ELN FBN1
5 hormone receptor binding GO:0051427 8.62 NPPA NPPB

Sources for Heart Valve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....